Sales Force Effectiveness USA 2010

eyeforpharma17-18 May 2010, Princeton, NJ, USA.
SFE USA is a premier conference for pharma. Learn how to develop a winning sales strategy from pharma leaders. 10 Industry VPs will deliver sessions on healthcare reform, customer-centric models, and CRM tools.

SFE USA Program

Pharma In 2010 And Beyond

  • Lean, Mean, Switching machines- What is the future of Sales Force Effectiveness?
    Tony Fross, Senior Director WBB Business Excellence Group, Pfizer
  • Mergers & Acquisitions: What does the future hold?
    Richard Skelly, Senior Director Commercial Evaluations, AstraZeneca
  • Emerging Markets: Building BRIC(s) and Blocs
    Charlotte Sibley, Senior Vice President CBS Business Management, Shire
  • The future of pharma rests on the impending Health Care bill – be prepared and understand the implications
    Pharma Vice President confirmed, Genentech

Sales Excellence

  • Achieve more with less: Which commercial model will be most successful for your company?
    Barry Duke, Vice President Sales, Genzyme
  • Insights into Taro's commercial model strategies
    Joe Malta, Vice President Sales & Marketing, Taro Pharmaceuticals
  • The optimal size of your workforce: How small is big enough?
    Tracy Mills, Senior Director Sales Force Effectiveness, Endo Pharmaceuticals
  • Target managed markets and bring value to these powerful stakeholders
    Don Sawyer, Vice President Commercial Operations, AstraZeneca
  • How to ensure a long-term relationship with your key accounts
    Tony Zecca, Senior Director Sales Strategy, Effectiveness & Innovation, AstraZeneca

Sales Tools And Technology

  • Multi-Channel Management: Integrating promotion effectively across all channels
    Paulash Mohsen, VP Multichannel Marketing, Pfizer
  • Capitalise on the potential of e-detailing to reduce your marketing costs
    John Rotondo, VP & General Manager Commercial Operations, Bayer
  • Case Study: Closed Loop Marketing In A multi-channel environment
    Marc Valdiviezo, Director Marketing Excellence, Sanofi-Aventis
  • What technology should you provide your sales force to achieve optimum sales effectiveness?
    Edson Gemo, Senior Director Business Technology Sales Force Effectiveness Solution Center, Pfizer
    Steve Winawer, Senior Director, US Business Technology, Commercial Operations, Patient & Physician Marketing, Pfizer

Training And Development

  • The Evolution of Physician Behaviour and Implications for New Physician Access Models
    Mark Gleason, Senior Vice President, Corporate Development, Aptilon
  • SUPER PANEL: Scientist Vs salesman: Which approach will enable your sales reps to raise their value to the industry?
    Tim Ryan, Executive Director, Boehringer Ingelheim
    Christine Barczak, East Area Vice Presidnet, GSK
    Todd Lambert, Vice President Sales, Shire,
    Don Hribek, Senior Director of Strategic Accounts, EMD Serono
    Moderator: Greg Neal, Managing Partner, Rx Business Advantage Consulting
  • A sales force to be reckoned with: Transforming Sales Forces with talent upgrades, skills training, and business processes
    Joe Coffey, Vice President Sales, Baxter
  • Case Study: Discover the methodology behind successful training delivery
    Mike Capaldi, AVP Sales Training & Leadership Development, Sanofi-Aventis
  • Value Creation- The Next Frontier for Pharma
    Angela Bakker Lee, Principal, ZS Associates

For further information and registration, please visit:
http://www.eyeforpharma.com/sfeusa

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...